YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Changes in Intestinal Damage and Bacterial Translocation with Time after Administration of Diclofenac

Diclofenac 투여 후 시간경과에 따른 장손상과 장내세균전위의 변화

  • Kim, Eun-Jeong (Korea Health Industry Developement Institute) ;
  • Kim, Jeong-Wook (Department of Internal Medicine, Chungang University College of Medicine)
  • 김은정 (한국보건산업진흥원) ;
  • 김정욱 (중앙대학교 의과대학 내과학교실)
  • Published : 2008.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Non-steroidal anti-inflammatory drug (NSAID)-induced gut damage and bacterial translocation (BT) have not been studies well, especially from the perspective of time after administration of NSAIDs. We therefore examined these changes in animals. The study was performed on 5 groups of rat; a control group (group A) and diclofenac groups (groups B, C, E, and F). Rats in the diclofenac groups were orally administered diclofenac sodium before intestinal permeability (IP) measurement (group B, 1 h before measurement; group C, 10 h before; group D, 22 h before; and group E, 52 h before). The IP, stool pellet number, serum biochemical profile, enteric bacterial number, and BT in the mesenteric lymph nodes (MLNs), liver, spleen, kidney and heart were measured. The administration of diclofenac resulted in significantly increased IP, caused intestinal protein loss, decreased stool pellet number, caused enteric bacterial overgrowth and increased BT in multiple organs in groups A, B, C, and D. IF, intestinal protein loss, and the BT in the liver and the spleen in group E were decreased than those in group D. There were no differences in the other parameters between group D and E. In the recovery phase of the diclofenac-induced gut damage, enteric bacterial overgrowth and BT in the kidneys and the heart did not change while the BT in the reticuloendothelial systems such as in the MLNs and liver was decreased.

Keywords

References

  1. Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D. and Russell, R. I. : Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N. Engl. J. Med. 327, 749 (1992) https://doi.org/10.1056/NEJM199209103271101
  2. Bjarnason, I., Zanelli, G., Smith, T., Prouse, P., Williams, P., Smethurst, P., Delacey, G., Gumpel, M. J. and Levi, A. J. : Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 93, 480 (1987) https://doi.org/10.1016/0016-5085(87)90909-7
  3. Reuter, B. K., Davies, N. M. and Wallace, J. L. : Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112, 109 (1997) https://doi.org/10.1016/S0016-5085(97)70225-7
  4. Davies, N. M., Saleh, J. Y. and Skjodt, N. M. : Detection and prevention of NSAID-induced enteropathy. J. Pharm. Pharm. Sci. 3, 137 (2000)
  5. Berg, R. D. : Bacterial translocation from the gastrointestinal tract. Adv. Exp. Med. Biol. 473, 11 (1999)
  6. Page, J. and Henry, D. : Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch. Intern. Med. 160, 777 (2000) https://doi.org/10.1001/archinte.160.6.777
  7. Rauchhaus, M., Sharma, R. and Bolger, A. : NSAIDs, intestinal cell integrity, and bacterial translocation in chronic heart failure. Arch. Intern. Med. 160, 3004 (2000) https://doi.org/10.1001/archinte.160.19.3004
  8. Krack, A., Sharma, R., Figulla, H. R. and Anker, S. D. : The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur. Heart. J. 26, 2368 (2005) https://doi.org/10.1093/eurheartj/ehi389
  9. Brinkmann, A., Wolf, C. F., Berger, D., Kneitinger, E., Neumeister, B., Buchler, M., Radermacher, P., Seeling, W. and Georgieff, M. : Perioperative endotoxemia and bacterial translocation during major abdominal surgery: evidence for the protective effect of endogenous prostacyclin? Crit. Care. Med. 24, 1293 (1996) https://doi.org/10.1097/00003246-199608000-00005
  10. Wright, M. R., Davies, N. M. and Jamali, F. : Toxicokinetics of indomethacin-induced intestinal permeability in the rat. Pharmacol. Res. 35, 499 (1997) https://doi.org/10.1006/phrs.1997.0194
  11. Atchison, C. R., West, A. B., Balakumaran, A., Hargus, S. J., Pohl, L. R., Daiker, D. H., Aronson, J. F., Hoffmann, W. E., Shipp, B. K. and Treinen-Moslen M. : Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 119, 1537 (2000) https://doi.org/10.1053/gast.2000.20186
  12. Nakamura, J., Takada, S., Ohtsuka, N., Heya, T., Yamamoto, A., Kimura, T. and Sezaki, H. : An assessment of indomethacininduced gastrointestinal mucosal damage in-vivo: enhancement of urinary recovery after oral administration of phenolsulfonphthalein in rats. J. Pharm. Pharmacol. 35, 369 (1983) https://doi.org/10.1111/j.2042-7158.1983.tb02958.x
  13. Zittel, T. T., Lloyd, K. C., Rothenhofer, I., Wong, H., Walsh, J. H. and Raybould, H. E. : Calcitonin gene-related peptide and spinal afferents partly mediate postoperative colonic ileus in the rat. Surgery 123, 518 (1998) https://doi.org/10.1067/msy.1998.88090
  14. Pardo, A., Bartoli, R., Lorenzo-Zuniga, V., Planas, R., Vinado, B., Riba, J., Cabre, E., Santos, J., Luque, T., Ausina, V. and Gassull, M. A. : Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 31, 858 (2000) https://doi.org/10.1053/he.2000.5746
  15. Kotanko, P., Carter, M. and Levin, N. W. : Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol. Dial. Transplant. 21, 2057 (2006) https://doi.org/10.1093/ndt/gfl281